Protalix BioTherapeutics (PLX) Current Assets (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Current Assets of $86.4 million for Q1 2026, up 42.7% year-over-year from $60.5 million in Q1 2025, and up 29.52% quarter-over-quarter from $66.7 million in Q4 2025.
Protalix BioTherapeutics (PLX) Current Assets (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $86.4 million for Q1 2026.
- In Q1 2026, Current Assets rose 42.7% year-over-year to $86.4 million; the TTM figure through Mar 2026 stood at $86.4 million (up 42.7% YoY), while the FY2025 annual figure was $66.7 million, up 10.98% from the prior year.
- Current Assets for Q1 2026 stood at $86.4 million, up from $66.7 million in the prior quarter.
- The five-year high for Current Assets was $86.4 million in Q1 2026, with the low at $44.9 million in Q4 2022.
- The 5-year median for Current Assets is $65.5 million (2025), against an average of $63.2 million.
- The sharpest annual moves came in 2022 and 2023: Current Assets slumped 48.19% in 2022, then surged 58.69% in 2023.
- Protalix BioTherapeutics' Current Assets stood at $44.9 million in 2022, then surged by 55.82% to $69.9 million in 2023, then decreased by 14.09% to $60.1 million in 2024, then grew by 10.98% to $66.7 million in 2025, then increased by 29.52% to $86.4 million in 2026.
- Business Quant data shows PLX's Current Assets at $86.4 million in Q1 2026, $66.7 million in Q4 2025, and $66.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 92.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.22 Mn |
| Mar 31, 2026 | 86.36 Mn |
| Dec 31, 2025 | 66.67 Mn |
| Sep 30, 2025 | 66.50 Mn |
| Jun 30, 2025 | 65.49 Mn |
| Mar 31, 2025 | 60.51 Mn |
| Dec 31, 2024 | 60.08 Mn |
| Sep 30, 2024 | 47.85 Mn |
| Jun 30, 2024 | 77.37 Mn |
| Mar 31, 2024 | 75.40 Mn |
| Dec 31, 2023 | 69.93 Mn |
| Sep 30, 2023 | 72.62 Mn |
| Jun 30, 2023 | 73.58 Mn |
| Mar 31, 2023 | 55.40 Mn |
| Dec 31, 2022 | 44.88 Mn |
| Sep 30, 2022 | 45.76 Mn |
| Jun 30, 2022 | 49.70 Mn |
| Mar 31, 2022 | 56.54 Mn |
| Dec 31, 2021 | 61.67 Mn |
| Sep 30, 2021 | 71.22 Mn |